ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Systemic Piezo1 activation improves cerebrovascular function in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Progranulin haploinsufficiency remodels the cerebral microvasculature and neurovascular unit.bioRxiv : the preprint server for biology · 2026Article
- Voltage-Dependent Ion Channels in Vascular Endothelial Cells: An Unexpected Signaling Pathway in Non-Excitable Cells.Biomedicines · 2026Review
- The Emerging Role of Endothelial Ion Channels in the Control of Human Microcirculation.International journal of molecular sciences · 2026Review
- Modulation of ion channels as emerging therapeutic targets in the treatment of diabetic neuropathy.EXCLI journal · 2026Review
- Systemic Piezo1 activation improves cerebrovascular function in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
introductionCerebral blood flow (CBF) reductions and impaired functional hyperemia (FH) are early features of Alzheimer's disease (AD) that contribute to disease progression. Here, we investigated whether systemic activation of the mechanosensitive ion channel Piezo1 affects cerebrovascular deficits in an AD mouse model.
methodsUsing two-photon in vivo imaging and laser-speckle imaging, we determined CBF, capillary stalling, and FH in the 5xFAD model of AD.
resultsWe observed increased capillary stalling and reduced CBF and FH to whisker stimulation in 5xFAD mice compared to wild-type controls. The systemic administration of the Piezo1 agonist Yoda1 led to a ≈ 65% reduction in capillary stalls, increased CBF, and significantly improved FH in response to whisker stimulation, restoring CBF responses in 5xFAD mice to levels comparable to controls. DISCUSSION: These results suggest that Piezo1 activation improves microvascular flow and neurovascular coupling in AD, highlighting Piezo1 as a promising therapeutic target for early cerebrovascular dysfunction during AD. HIGHLIGHTS: An Alzheimer's disease (AD) animal model demonstrates reduced brain capillary blood flow and impaired neurovascular coupling. Pharmacological activation of Piezo1 at the systemic level improves blood flow and functional hyperemia during AD. Piezo1 is involved in cerebrovascular dysfunction associated with AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.